The life and times of ivermectin - a success story (Q35954279)

11 August 2017

1 reference

title

The life and times of ivermectin - a success story (English)

1 reference

11 August 2017

0 references

2

Andy Crump

1 reference

11 August 2017

Satoshi Omura

1

1 reference

PubMed ID

15550944

11 August 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

Nature Reviews Microbiology

11 August 2017

1 reference

11 August 2017

2

1 reference

11 August 2017

12

1 reference

11 August 2017

984-989

1 reference

https://scigraph.springernature.com/pub.10.1038/nrmicro1048

11 August 2017

0 references

cites work

Avermectins, New Family of Potent Anthelmintic Agents: Producing Organism and Fermentation

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Avermectins, New Family of Potent Anthelmintic Agents: Isolation and Chromatographic Properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Avermectins, New Family of Potent Anthelmintic Agents: Efficacy of the B 1a Component

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Genome sequence of an industrial microorganism Streptomyces avermitilis: deducing the ability of producing secondary metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Complete genome sequence and comparative analysis of the industrial microorganism Streptomyces avermitilis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Actions of dihydroavermectin B1a on insect muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Haemonchus contortus: ivermectin-induced paralysis of the pharynx.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Postsynaptic inhibition of invertebrate neuromuscular transmission by avermectin B1a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Eliminating onchocerciasis as a public health problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Efficacy and tolerance of ivermectin in human onchocerciasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Ivermectin in onchocerciasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Controlled trial and dose-finding study of ivermectin for treatment of onchocerciasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

The impact of five years of annual ivermectin treatment on skin microfilarial loads in the onchocerciasis focus of Asubende, Ghana

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

A community trial of ivermectin for onchocerciasis in Sierra Leone: clinical and parasitological responses to four doses given at six-monthly intervals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Treatment of onchocerciasis. The ocular effects of ivermectin and diethylcarbamazine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Community-based treatment of onchocerciasis with ivermectin: safety, efficacy, and acceptability of yearly treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Adverse events following mass ivermectin therapy for onchocerciasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Economic evaluation of Mectizan distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

The delivery of ivermectin (Mectizan).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Willingness to pay for community-based ivermectin distribution: a study of three onchocerciasis-endemic communities in Nigeria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Community-directed treatment with ivermectin in two Nigerian communities: an analysis of first year start-up processes, costs and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

A field study of the effects of ivermectin on ectoparasites of man

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Selection at a P-glycoprotein gene in ivermectin- and moxidectin-selected strains of Haemonchus contortus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Use of P-glycoprotein gene probes to investigate anthelmintic resistance in Haemonchus contortus and comparison with Onchocerca volvulus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Ivermectin, a new broad-spectrum antiparasitic agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Avermectin B1a irreversibly blocks postsynaptic potentials at the lobster neuromuscular junction by reducing muscle membrane resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Effect of single-dose ivermectin therapy on human Onchocerca volvulus infection with onchocercal ocular involvement.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Ivermectin: A Potent New Antiparasitic Agent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Clinical and parasitological responses after up to 6.5 years of ivermectin treatment for onchocerciasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Concurrent parasitic infections in onchocerciasis and the occurrence of adverse reactions after ivermectin treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Optimising the benefits of anthelmintic treatment in children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

Effects of multiple monthly doses of ivermectin on adult Onchocerca volvulus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

inferred from DOI database lookup

7 January 2021

based on heuristic

Effects of three-month doses of ivermectin on adult Onchocerca volvulus

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1048

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRMICRO1048

1 reference

11 August 2017

1 reference

PubMed ID

15550944